Which of the following statements is true regarding the use of ticlopidine hydrochloride?

Ticlopidine hydrochloride is an antiplatelet medication that is primarily used to reduce the risk of thrombotic stroke and to prevent stent thrombosis in patients undergoing coronary stenting. Regular monitoring of complete blood counts (CBC) is essential for patients taking ticlopidine because the medication can cause serious hematologic side effects, including neutropenia (a decrease in white blood cells) and thrombocytopenic purpura (a decrease in platelets). These conditions can significantly increase the risk of serious infections and bleeding complications.

By performing regular CBC monitoring, healthcare providers ensure the early detection of these potential side effects, allowing for timely interventions if necessary. This monitoring is particularly critical during the first three months of therapy when the risk of these adverse effects is highest.

In contrast, the other options do not correctly reflect the key aspects of care associated with ticlopidine use. Mixing it with alcohol can increase the risk of gastrointestinal bleeding; it is not recommended to take the medication only when symptoms are present since it is preventive; and it is important to be cautious with herbal supplements, as they may interact with ticlopidine and alter its effectiveness or side effect profile. Regular CBC monitoring remains a fundamental part of ensuring patient safety while on ticlop